Turning Point Therapeutics (Nasdaq:TPTX) - Cotización, noticias y análisis

Resumen de acción TPTX

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer.

Acerca de la empresa

TPTX fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 73.92%

Análisis de riesgos

Alta volatilidad del precio de la acción en los últimos 3 meses

No tiene ingresos significativos ($1M)

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Competidores de Turning Point Therapeutics, Inc.

Chinook Therapeutics

NasdaqGS:KDNY

US$2.9b

Alpine Immune Sciences

NasdaqGM:ALPN

US$4.2b

Crinetics Pharmaceuticals

NasdaqGS:CRNX

US$3.3b

Halozyme Therapeutics

NasdaqGS:HALO

US$5.0b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Turning Point Therapeutics
Historical stock prices
Current Share Price	US$76.01
52 Week High	US$82.20
52 Week Low	US$23.77
Beta	-0.19
1 Month Change	1.58%
3 Month Change	114.96%
1 Year Change	18.90%
3 Year Change	45.39%
5 Year Change	n/a
Change since IPO	163.01%

Noticias y actualizaciones recientes

Recent updates

Bristol Myers U.S., German antitrust filings for Turning Point expected very soon - report

Jul 21

We Think Turning Point Therapeutics (NASDAQ:TPTX) Can Afford To Drive Business Growth

Mar 23

Companies Like Turning Point Therapeutics (NASDAQ:TPTX) Are In A Position To Invest In Growth

Dec 06

The Take On Turning Point Therapeutics

Dec 03

Industry Analysts Just Made A Sizeable Upgrade To Their Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Revenue Forecasts

Aug 15

Turning Point Therapeutics (NASDAQ:TPTX) Is In A Strong Position To Grow Its Business

Aug 04

Turning Point Therapeutics gets FDA orphan drug status for TPX-0022 in gastric cancer

Jun 17

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 08

Have Insiders Been Selling Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Shares This Year?

Feb 26

Turning Point Therapeutics' repotrectinib shows promising results in lung cancer study

Jan 29

Analysts' Revenue Estimates For Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Are Surging Higher

Jan 22

Turning Point Therapeutics' lead candidate nabs accelerated review for lung cancer

Dec 08

Turning Point Therapeutics EPS beats by $0.12, beats on revenue

Nov 12

Rentabilidad de los accionistas

	TPTX	US Biotechs	Mercado US
7D	1.3%	0.4%	1.0%
1Y	18.9%	0.9%	21.9%

Rentabilidad vs. Industria: TPTX superó al sector US Biotechs , que obtuvo un rendimiento del -3.7% el año pasado.

Rentabilidad vs. Mercado: TPTX superó al mercado US, que obtuvo un rendimiento del 19.3% el año pasado.

Volatilidad de los precios

Is TPTX's price volatile compared to industry and market?
TPTX volatility
TPTX Average Weekly Movement	34.2%
Biotechs Industry Average Movement	11.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de TPTX ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de TPTX ha aumentado de 20% a 34% en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2013	267	Athena Countouriotis	www.tptherapeutics.com

Resumen de fundamentos de Turning Point Therapeutics, Inc.

¿Cómo se comparan los beneficios e ingresos de Turning Point Therapeutics con su capitalización de mercado?
Estadísticas fundamentales de TPTX
Capitalización bursátil	US$3.81b
Beneficios(TTM)	-US$342.31m
Ingresos (TTM)	US$1.01m

3,776x

Ratio precio-ventas (PS)

-11.1x

Ratio precio-beneficio (PE)

¿Está TPTX sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de TPTX
Ingresos	US$1.01m
Coste de los ingresos	US$0
Beneficio bruto	US$1.01m
Otros gastos	US$343.32m
Beneficios	-US$342.31m

Últimos beneficios comunicados

Jun 30, 2022

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-6.84
Margen bruto	100.00%
Margen de beneficio neto	-33,959.03%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado TPTX a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción TPTX

Recompensas

Análisis de riesgos

Competidores de Turning Point Therapeutics, Inc.

NasdaqGS:KDNY

US$2.9b

NasdaqGM:ALPN

US$4.2b

NasdaqGS:CRNX

US$3.3b

NasdaqGS:HALO

US$5.0b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Turning Point Therapeutics, Inc.(NasdaqGS:TPTX) dropped from NASDAQ Composite Index

Turning Point Therapeutics, Inc. Announces Executive Changes

Consensus forecasts updated

Turning Point Therapeutics, Inc. Provides Operational and Clinical Update

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Executive VP & CFO recently sold US$89k worth of stock

Recent updates

Turning Point Therapeutics, Inc.(NasdaqGS:TPTX) dropped from NASDAQ Composite Index

Turning Point Therapeutics, Inc. Announces Executive Changes

Consensus forecasts updated

Turning Point Therapeutics, Inc. Provides Operational and Clinical Update

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Executive VP & CFO recently sold US$89k worth of stock

Bristol Myers U.S., German antitrust filings for Turning Point expected very soon - report

Turning Point Therapeutics, Inc.(NasdaqGS:TPTX) dropped from NASDAQ Biotechnology Index

Price target decreased to US$79.50

Price target decreased to US$87.71

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Turning Point Therapeutics, Inc. (NasdaqGS:TPTX) for $3.8 billion.

Consensus forecasts updated

Turning Point Therapeutics, Inc. Announces Appointment of Steve Sabus as Chief Commercial Officer, Effective as of May 31, 2022

Price target decreased to US$105

Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With One Prior ROS1 Tyrosine Kinase Inhibitor and no Prior Chemotherapy

Turning Point Therapeutics, Inc., Annual General Meeting, Jun 16, 2022

High number of new and inexperienced directors

Turning Point Therapeutics, Inc. Announces Positive Topline Results from the Registrational TRIDENT-1 Study Across All Four ROS1-Positive Advanced Non-Small Cell Lung Cancer Cohort

Turning Point Therapeutics, Inc. Appoints Brian Sun as Senior Vice President and General Counsel, Effective April 11, 2022

We Think Turning Point Therapeutics (NASDAQ:TPTX) Can Afford To Drive Business Growth

Turning Point Therapeutics, Inc. Announces the Resignation of Siegfried Reich as Executive Vice President and Chief Scientific Officer

Full year 2021 earnings: EPS exceeds analyst expectations

Price target decreased to US$119

Turning Point Therapeutics, Inc. Announces Retirement of Annette North as Executive Vice President, General Counsel and Corporate Secretary, Effective March 4, 2022

President recently sold US$108k worth of stock

Turning Point Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for Combination of Elzovantinib and Aumolertinib in Egfr Mutant Met-Amplified Non-Small Cell Lung Cancer

Turning Point Therapeutics, Inc. Provides Updates and Anticipates 2022 Clinical and Discovery Pipeline Milestones

Turning Point Therapeutics, Inc. Announces Regulatory Updates for Its Lead Drug Candidate, Repotrectinib, ROS1/TRK Inhibitor, and for Elzovantinib (TPX-0022), Its Drug Candidate Targeting MET, CSF1R and SRC

Companies Like Turning Point Therapeutics (NASDAQ:TPTX) Are In A Position To Invest In Growth

The Take On Turning Point Therapeutics

Price target decreased to US$134

Turning Point Therapeutics Announces Early Clinical Data for Repotrectinib in NTRK Fusion-Positive Advanced Solid Tumors Selected for Late-Breaker Plenary Presentation at 2021 AACR-NCI-EORTC Conference

Executive VP exercised options and sold US$630k worth of stock

Turning Point Therapeutics Initiates TRIDENT-2 Clinical Study Investigating Repotrectinib-Trametinib Combination in KRAS G12D Mutated Advanced Solid Tumors

Consensus revenue estimates increase to US$30.4m

Industry Analysts Just Made A Sizeable Upgrade To Their Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Revenue Forecasts

Turning Point Therapeutics (NASDAQ:TPTX) Is In A Strong Position To Grow Its Business

Executive VP & Chief Commercial Officer recently sold US$140k worth of stock

Chairman of the Board recently bought US$163k worth of stock

Turning Point Therapeutics, Inc. Grants FDA Orphan Drug Designation for TPX-0022 in Gastric Cancer

Executive VP exercised options and sold US$900k worth of stock

Turning Point Therapeutics gets FDA orphan drug status for TPX-0022 in gastric cancer

Senior VP of Finance & Administration and Principal Accounting Officer has left the company

Consensus forecasts updated

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Turning Point Therapeutics, Inc. Appoints Brian Baker as the Interim Principal Financial Officer

Turning Point Therapeutics, Inc. Announces Executive Changes, Effective March 31, 2021

Analysts update estimates

New 90-day low: US$103

Earnings beat expectations, revenue disappoints

Turning Point Therapeutics, Inc. Provides Operational and Clinical Updates

Have Insiders Been Selling Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Shares This Year?

Turning Point Therapeutics, Inc. to Report Q4, 2020 Results on Mar 01, 2021

President exercised options and sold US$8.1m worth of stock

New 90-day high: US$140

Price target raised to US$160

Turning Point Therapeutics Reports Updated Interim Data from Registrational Phase 2 Trident-1 Study of Repotrectinib in Patients With ROS1-Positive TKI-Naïve Non-Small Cell Lung Cancer

Turning Point Therapeutics' repotrectinib shows promising results in lung cancer study

Analysts' Revenue Estimates For Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Are Surging Higher